Submit Manuscript  

Article Details


Novel Vaccine Candidates against Tuberculosis

Author(s):

Zhihao Li, Changping Zheng, Marco Terreni, Lisa Tanzi, Matthieu Sollogoub and Yongmin Zhang*   Pages 1 - 23 ( 23 )

Abstract:


Ranking above AIDS, tuberculosis (TB) is the ninth leading cause of death affecting and killing many individuals every year. Drugs' efficacy is limited by serials of problems such as multi-drug resistance (MDR) and extensively-drug resistance (XDR). Meanwhile, the only licensed vaccine BCG (Bacillus Calmette–Guérin) existing for over 90 years is not effective enough. Consequently, it is essential to develop novel vaccines for TB prevention and immunotherapy. This paper provides an overall review of the TB prevalence, immune system response against TB and recent progress of TB vaccine research and development. Several vaccines in clinical trials are described as well as LAM-based candidates.

Keywords:

Tuberculosis, Vaccine, Lipoarabinomannan.

Affiliation:

Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire (UMR 8232), 4 Place Jussieu, 75005 Paris, Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire (UMR 8232), 4 Place Jussieu, 75005 Paris, Drug Sciences Department, University of Pavia, Viale Taramelli 12, 27100 Pavia, Drug Sciences Department, University of Pavia, Viale Taramelli 12, 27100 Pavia, Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire (UMR 8232), 4 Place Jussieu, 75005 Paris, Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire (UMR 8232), 4 Place Jussieu, 75005 Paris



Read Full-Text article